Losing muscle mass can decrease metabolism, increase the risk of diabetes and obesity, and increase the risk of falls and fractures in older adults
O'Neil et al., 2018), five recorded changes of BMI, blood pressure, CRP, and lipid profiles (Wilding et al., 2021
While Liraglutide demonstrated similar outcomes, Tirzepatide was observed to outperform it across multiple measures by a significant margin
TIMP-1 and TIMP-2 tissue inhibitors of metalloproteinases are upregulated, further tipping the balance toward matrix preservation
10.1016/j.ejphar.2011.05.038 [DOI] [PubMed] [Google Scholar] Ilic S., Drmic D., Zarkovic K., Kolenc D., Coric M., Brcic L., et al
Tirzepatide is administered via a once-weekly injection, which can be done at home or in a clinical setting